GlassScriptPhysician profile
Abdol A Mojab
NPI 1194744136
$9,337.52
in general payments reported to CMS, 2019-2025
52 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,287 · 2020: $993 · 2021: $3,020 · 2022: $2,565 · 2023: $361 · 2024: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $333 · Food and Beverage: $117 · Education: $22.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $333.32 |
| Food and Beverage | $117.11 |
| Education | $22.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,252.35 | 2019-2024 | |
| Amgen INC. | $680.44 | 2019-2022 | |
| Pfizer INC. | $582.61 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $500.70 | 2019-2023 | Keytruda |
| Astrazeneca Pharmaceuticals LP | $448.25 | 2019-2023 | Calquence |
| Janssen Biotech, INC. | $424.60 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $422.51 | 2019-2022 | |
| Eisai INC. | $420.66 | 2019-2022 | |
| Abbvie INC. | $295.34 | 2019-2024 | |
| Glaxosmithkline, LLC. | $251.68 | 2021-2022 | |
| Celgene Corporation | $237.23 | 2019-2023 | Reblozyl |
| Seagen INC. | $210.37 | 2019-2022 | |
| Lilly USA, LLC | $198.93 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $160.38 | 2021-2022 | |
| Genentech USA, INC. | $157.52 | 2019-2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdol Mojab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.